Radiodermatitis - Pipeline Review, H1 2020
Radiodermatitis - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H1 2020, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.
Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H1 2020, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.
Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Radiodermatitis - Overview
Radiodermatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Radiodermatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Radiodermatitis - Companies Involved in Therapeutics Development
Amryt Pharma Plc
BioCurity Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Foresee Pharmaceuticals Co Ltd
Jay Pharma Inc
KannaLife Sciences Inc
Matrix Biomed Inc
Noveome Biotherapeutics Inc
Regeneus Ltd
RepoCeuticals ApS
Sunny Pharmtech Inc
Radiodermatitis - Drug Profiles
Biologic for Dermatology and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birch bark extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerium oxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, Xerostomia And Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RS-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tempol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZM-241385 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Radiodermatitis - Dormant Projects
Radiodermatitis - Discontinued Products
Radiodermatitis - Product Development Milestones
Featured News & Press Releases
Dec 11, 2019: Kannalife announces filing of U.S. Patent 62/934,861 - Functionalized 1, 3 Benzene Diols and their method of use for the treatment of radiation dermatitis and other skin disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Radiodermatitis - Overview
Radiodermatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Radiodermatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Radiodermatitis - Companies Involved in Therapeutics Development
Amryt Pharma Plc
BioCurity Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Foresee Pharmaceuticals Co Ltd
Jay Pharma Inc
KannaLife Sciences Inc
Matrix Biomed Inc
Noveome Biotherapeutics Inc
Regeneus Ltd
RepoCeuticals ApS
Sunny Pharmtech Inc
Radiodermatitis - Drug Profiles
Biologic for Dermatology and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birch bark extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerium oxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, Xerostomia And Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RS-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tempol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZM-241385 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Radiodermatitis - Dormant Projects
Radiodermatitis - Discontinued Products
Radiodermatitis - Product Development Milestones
Featured News & Press Releases
Dec 11, 2019: Kannalife announces filing of U.S. Patent 62/934,861 - Functionalized 1, 3 Benzene Diols and their method of use for the treatment of radiation dermatitis and other skin disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Radiodermatitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Radiodermatitis - Pipeline by Amryt Pharma Plc, H1 2020
Radiodermatitis - Pipeline by BioCurity Pharmaceuticals Inc, H1 2020
Radiodermatitis - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Radiodermatitis - Pipeline by Foresee Pharmaceuticals Co Ltd, H1 2020
Radiodermatitis - Pipeline by Jay Pharma Inc, H1 2020
Radiodermatitis - Pipeline by KannaLife Sciences Inc, H1 2020
Radiodermatitis - Pipeline by Matrix Biomed Inc, H1 2020
Radiodermatitis - Pipeline by Noveome Biotherapeutics Inc, H1 2020
Radiodermatitis - Pipeline by Regeneus Ltd, H1 2020
Radiodermatitis - Pipeline by RepoCeuticals ApS, H1 2020
Radiodermatitis - Pipeline by Sunny Pharmtech Inc, H1 2020
Radiodermatitis - Dormant Projects, H1 2020
Radiodermatitis - Discontinued Products, H1 2020
Number of Products under Development for Radiodermatitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Radiodermatitis - Pipeline by Amryt Pharma Plc, H1 2020
Radiodermatitis - Pipeline by BioCurity Pharmaceuticals Inc, H1 2020
Radiodermatitis - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Radiodermatitis - Pipeline by Foresee Pharmaceuticals Co Ltd, H1 2020
Radiodermatitis - Pipeline by Jay Pharma Inc, H1 2020
Radiodermatitis - Pipeline by KannaLife Sciences Inc, H1 2020
Radiodermatitis - Pipeline by Matrix Biomed Inc, H1 2020
Radiodermatitis - Pipeline by Noveome Biotherapeutics Inc, H1 2020
Radiodermatitis - Pipeline by Regeneus Ltd, H1 2020
Radiodermatitis - Pipeline by RepoCeuticals ApS, H1 2020
Radiodermatitis - Pipeline by Sunny Pharmtech Inc, H1 2020
Radiodermatitis - Dormant Projects, H1 2020
Radiodermatitis - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Radiodermatitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Amryt Pharma Plc
BioCurity Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Foresee Pharmaceuticals Co Ltd
Jay Pharma Inc
KannaLife Sciences Inc
Matrix Biomed Inc
Noveome Biotherapeutics Inc
Regeneus Ltd
RepoCeuticals ApS
Sunny Pharmtech Inc
Number of Products under Development for Radiodermatitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Amryt Pharma Plc
BioCurity Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Foresee Pharmaceuticals Co Ltd
Jay Pharma Inc
KannaLife Sciences Inc
Matrix Biomed Inc
Noveome Biotherapeutics Inc
Regeneus Ltd
RepoCeuticals ApS
Sunny Pharmtech Inc
